Profil
Dr. Nick Flinn is Head-Preclinical Development at Amura Holdings Ltd.
Dr. Flinn was previously employed as a Principal by Medivir AB, a Principal by Acambis Plc, and a Principal by Incenta Ltd.
He received his undergraduate degree from the University of London and a doctorate degree from the University of London.
Ehemalige bekannte Positionen von Nick Flinn
| Unternehmen | Position | Ende |
|---|---|---|
| Incenta Ltd. | Corporate Officer/Principal | - |
Acambis Plc
 Acambis Plc BiotechnologyHealth Technology Acambis Plc develops biopharmaceutical products and vaccines. It offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline include ChimeriVax-JE, ChimeriVax-West Nile, and ChimeriVax-Dengue. The company was founded in 1992 and is headquartered in Cambridge, UK. | Corporate Officer/Principal | - |
| MEDIVIR AB | Corporate Officer/Principal | - |
Amura Holdings Ltd.
 Amura Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amura Holdings Ltd. was engaged in drug discovery for diseases, such as osteoporosis, osteoarthritis, bone metastasis, autoimmunity, chronic pain, and malaria. The firm developed a technology platform that provided turnkey solutions for the discovery of small-molecule inhibitors against cysteine peptidases. The company was founded by Daniel James William Roach on June 6, 20005 and was headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | - |
Ausbildung von Nick Flinn
| University of London | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| MEDIVIR AB | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Acambis Plc
Acambis Plc BiotechnologyHealth Technology Acambis Plc develops biopharmaceutical products and vaccines. It offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline include ChimeriVax-JE, ChimeriVax-West Nile, and ChimeriVax-Dengue. The company was founded in 1992 and is headquartered in Cambridge, UK. | Health Technology |
Amura Holdings Ltd.
Amura Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amura Holdings Ltd. was engaged in drug discovery for diseases, such as osteoporosis, osteoarthritis, bone metastasis, autoimmunity, chronic pain, and malaria. The firm developed a technology platform that provided turnkey solutions for the discovery of small-molecule inhibitors against cysteine peptidases. The company was founded by Daniel James William Roach on June 6, 20005 and was headquartered in Cambridge, the United Kingdom. | Health Technology |
| Incenta Ltd. |
